Warburg Research set a €115.00 ($141.98) price target on Merck KGaA (FRA:MRK) in a research report report published on Friday. The brokerage currently has a buy rating on the healthcare company’s stock.
Several other equities analysts also recently weighed in on MRK. UBS Group set a €120.00 ($148.15) target price on Merck KGaA and gave the company a buy rating in a research report on Monday, October 23rd. Commerzbank set a €103.00 ($127.16) target price on Merck KGaA and gave the company a neutral rating in a research report on Thursday, October 26th. Oddo Bhf set a €125.00 ($154.32) target price on Merck KGaA and gave the company a buy rating in a research report on Friday, October 27th. JPMorgan Chase & Co. set a €100.00 ($123.46) target price on Merck KGaA and gave the company a neutral rating in a research report on Wednesday, November 1st. Finally, equinet set a €112.00 ($138.27) target price on Merck KGaA and gave the company a buy rating in a research report on Friday, November 3rd. Eleven analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. The company presently has an average rating of Buy and an average target price of €107.57 ($132.80).
Merck KGaA (FRA:MRK) traded up €1.00 ($1.23) during midday trading on Friday, reaching €83.52 ($103.11). The company’s stock had a trading volume of 568,716 shares. The firm has a market cap of $10,790.00 and a P/E ratio of 19.56. Merck KGaA has a 52 week low of €80.50 ($99.38) and a 52 week high of €115.00 ($141.98).
TRADEMARK VIOLATION WARNING: This report was originally published by Week Herald and is owned by of Week Herald. If you are viewing this report on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The original version of this report can be accessed at https://weekherald.com/2018/02/17/merck-kgaa-mrk-given-a-115-00-price-target-by-warburg-research-analysts.html.
MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.